Table 3.
Cost from epidemiological changes of hypertension expected for the years 2015, 2016, 2017 in Mexico (in US$)
| Item cost | Year | |||
|---|---|---|---|---|
| 2015 | 2016 | 2017 | p value | |
| Direct costs | ||||
| Consultations/diagnosis | 342,503,700 | 358,813,400 | 391,432,800 | <0.001 |
| Drugs | 399,587,467 | 418,615,441 | 456,671,390 | <0.001 |
| Hospitalization | 313,961,277 | 328,911,814 | 358,812,888 | <0.001 |
| Nephropathy | 988,978,836 | 1,036,073,067 | 1,130,261,527 | <0.001 |
| Nonfatal myocardial infarction | 449,535,634 | 470,942,093 | 513,755,010 | <0.001 |
| Nonfatal stroke | 359,628,074 | 376,753,221 | 411,003,513 | <0.001 |
| Total direct costs | 2854,194,988 | 2,990,109,035 | 3,261,937,129 | <0.001 |
| Indirect costs | ||||
| Mortality | 474,872,870 | 497,485,864 | 542,711,851 | <0.001 |
| Permanent disability | 2342,709,670 | 2,454,267,274 | 2,677,382,480 | <0.001 |
| Temporary disability | 348,240,277 | 364,823,148 | 397,988,888 | <0.001 |
| Total indirect costs | 3,165,822,818 | 3,316,576,285 | 3,618,083,220 | <0.001 |
| TOTAL COSTS | 6,020,017,806 | 6,306,685,320 | 6,880,020,349 | <0.001 |
Source: Arredondo et al. (2014) [17] Costos y consecuencias financieras del cambio en el perfil epidemiológico en México. INSP–University of Montreal-International Development Research Centre, 1999–2009. Update of probabilistic models, January 2015
Box–Pierce statistical test (P < 0.001)
Exchange rate: January 2015, 1 US$ = 14.85 Mexican $